Division of Orbital, Ophthalmic Plastic and Reconstructive Surgery, Clinica de Oftalmología de Cali, Universidad del Valle, Cali, Colombia.
Ophthalmology. 2010 May;117(5):1037-40. doi: 10.1016/j.ophtha.2009.09.028. Epub 2010 Jan 15.
To determine the outcome and safety of nonlaser endonasal dacryocystorhinostomy (NLEN-DCR) with the use of adjunctive mitomycin C (MMC) in congenital, traumatic, and primary acquired nasolacrimal duct obstruction in adults.
Retrospective, nonrandomized, noncomparative, case series.
One hundred ninety-three consecutive adult patients underwent NLEN-DCR with the use of adjunctive MMC. Thirty-one patients had a simultaneous bilateral procedure performed.
All patients underwent a standardized procedure, with an endonasal approach to the lacrimal sac, surgical removal of nasal mucosa, lacrimal bone, and a fragment of the frontal process of the maxilla. The medial wall of the lacrimal sac was removed completely, and a neurosurgical cottonoid soaked in MMC at 0.5 mg/ml was placed at the osteotomy site for 10 minutes. All patients underwent bicanalicular silicone intubation.
Resolution of epiphora, absence of discharge, and patency of the ostium confirmed by irrigation at 6 months.
The NLEN-DCR procedure with adjunctive MMC was successful in 212 (95%) cases. The mean follow-up was 18.2 months. Intubation of more than 3 months was associated with a higher rate of obstruction (P<0.00018, Fisher exact test), with 9 eyes of 8 patients losing patency. Age, diagnosis, side operated, or infection at the time of surgery had no influence on the final outcome. No significant complications were encountered.
Results suggest that NLEN-DCR with MMC is a safe and successful procedure for the treatment of congenital, traumatic, and primary acquired nasolacrimal duct obstruction in adults. It has the advantage of leaving no scar and of preserving the medial canthal structures. It can be performed successfully as a simultaneous bilateral procedure.
评估成人先天性、外伤性和原发性鼻泪管阻塞患者行非激光经鼻内泪囊鼻腔吻合术(NLEN-DCR)联合丝裂霉素 C(MMC)的疗效和安全性。
回顾性、非随机、非对照、病例系列研究。
193 例连续成人患者接受 NLEN-DCR 联合丝裂霉素 C 治疗。31 例患者同时行双侧手术。
所有患者均采用经鼻内镜入路至泪囊,切除鼻内黏膜、泪骨和部分上颌骨额突,完全去除泪囊内侧壁,在骨切面上放置浸有 0.5mg/ml 丝裂霉素 C 的神经外科棉片 10 分钟。所有患者均行双泪道硅胶管留置。
6 个月时通过冲洗确认溢泪缓解、无分泌物、吻合口通畅。
212 例(95%)患者行 NLEN-DCR 联合丝裂霉素 C 治疗成功。平均随访 18.2 个月。留置时间超过 3 个月与吻合口阻塞率升高相关(P<0.00018,Fisher 确切概率检验),8 例 9 眼失去通畅。年龄、诊断、手术侧或手术时是否存在感染对最终结果无影响。未发生明显并发症。
结果表明,成人先天性、外伤性和原发性鼻泪管阻塞患者行 NLEN-DCR 联合丝裂霉素 C 治疗安全有效,具有不留瘢痕和保留内眦结构的优点,可成功同期行双侧手术。